The following message appeared on the NFZ website:
- Ozempic and Trulicity are drugs for type 2 diabetes patients.
- They give patients a chance to live longer and better. The drugs make it possible for patients to wean off insulin or reduce weight under control.
- Patients who have indications for therapy with these drugs buy them with reimbursement from the National Health Service. However, these drugs are often prescribed at a discount for those without reimbursement indications, as preparations for weight loss.
- The effect? Drugs are in short supply, and the National Health Fund has less money to reimburse therapies for patients who need them.
- Both preparations have already made it to the anti-vivisection list, and the National Health Service is monitoring whether they are prescribed with reimbursement for patients with diabetes.
What are the drugs in the GLP-1 analog group?
Ozempic (semaglutidum) and Trulicity (dulaglutidum), drugs in the group of glucagon-like peptide 1 (GLP-1) analogs, are used to treat type 2 diabetes. They stabilize blood glucose levels, but do not increase the risk of sugar drop. Type 2 diabetes is a chronic disease that can lead to disability from complications and even premature death. It is estimated that more than 1.2 million people in Poland have type 2 diabetes. The use of Ozempic or Trulicity allows type 2 diabetes patients previously treated with insulin to reduce doses and simplify insulin therapy. With these drugs, it i...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
